TR422 for pulmonary arterial hypertension

Other than a clinical application for ED, topical vardenafil gel has a potential in treatment of pulmonary arterial hypertension (PAH). Although some PDE5 inhibitors such as Revatio (20 mg sildenafil) and Adcirca (40 mg tadalafil) are used to manage the life quality of PAH patients, the serum peak in oral delivery always surges day after day to give the cardiovascular system long term pressures and even cause life threatening. Our product, TR422, is a vardenafil gel for topical use. It can be spread on skin to let vardenafil penetrate through and be stored in tissue for sustained release. Therefore, the slow and long term released vardenafil will enter blood stream at a clinically effective concentration to alleivate the pressure of pulmonary artery. It is believed that the degree and possibility of systemic side effects including sudden death will be exetremely reduced once PAH patients receive TR422 treatment continuously.